UCB SA (OTCMKTS:UCBJF – Get Free Report)’s share price passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $186.09 and traded as high as $195.83. UCB shares last traded at $192.00, with a volume of 251 shares.
UCB Price Performance
The business’s 50 day moving average is $185.98 and its 200-day moving average is $174.38. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- What Is WallStreetBets and What Stocks Are They Targeting?
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- 3 Tickers Leading a Meme Stock Revival
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- What is the S&P/TSX Index?
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
